Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1180P | ISIN: US67576A1007 | Ticker-Symbol: 0OT
Tradegate
28.03.24
20:14 Uhr
8,460 Euro
+0,035
+0,42 %
1-Jahres-Chart
OCULAR THERAPEUTIX INC Chart 1 Jahr
5-Tage-Chart
OCULAR THERAPEUTIX INC 5-Tage-Chart
RealtimeGeldBriefZeit
8,3208,56028.03.
8,3158,53028.03.

Aktuelle News zur OCULAR THERAPEUTIX Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiOcular Therapeutix, Inc.: Ocular Therapeutix To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)3
DiOcular Therapeutix files to sell 43.22M shares of common stock for holders3
13.03.Decoding 6 Analyst Evaluations For Ocular Therapeutix12
12.03.These Analysts Boost Their Forecasts On Ocular Therapeutix After Q4 Results4
12.03.JMP Securities boosts Ocular Therapeutix stock target to $2413
12.03.ACADIA Pharmaceuticals, Ocular Therapeutix, Asana And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session6
11.03.Ocular Therapeutix Inc reports results for the quarter ended in December - Earnings Summary11
11.03.FLEX, OCUL and PRPL are among after hour movers2
11.03.OCULAR THERAPEUTIX, INC - S-8, Securities to be offered to employees in employee benefit plans1
11.03.Ocular Therapeutix: Q4 Earnings Insights1
11.03.Ocular Therapeutix GAAP EPS of -$0.35 misses by $0.05, revenue of $14.8M misses by $0.91M5
11.03.OCULAR THERAPEUTIX, INC - 10-K, Annual Report1
11.03.OCULAR THERAPEUTIX, INC - 8-K, Current Report1
11.03.Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Fourth Quarter and Full Year 2023 Results149Leadership Appointments Move Ocular Towards Being a Leader in Retinal Care Screening Underway in AXPAXLI Phase 3 SOL-1 Trial for Wet AMD Topline Clinical Data for AXPAXLI in Diabetic Retinopathy...
► Artikel lesen
10.03.Ocular Therapeutix Q4 2023 Earnings Preview16
08.03.Earnings Outlook For Ocular Therapeutix11
05.03.Ocular Therapeutix, Inc.: Ocular Therapeutix to Release Fourth Quarter and Full Year 2023 Results on March 11, 202413
28.02.$7M Bet On Ocular Therapeutix? Check Out These 3 Stocks Insiders Are Buying24
22.02.Ocular Therapeutix reshuffles leadership, aims for retina care leadership33
22.02.Ocular Therapeutix gains after $325M private placement41
Seite:  Weiter >>
58 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1